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Abstract
Parkinson’s  disease  (PD) results  from a complex interaction of  environmental  and
genetic influences on a background of aging. Regardless of etiology, significant clinical
advances rely on identifying the common biological pathways that underpin neuronal
degeneration. Oxidative stress is consistently reported as a hallmark feature of PD.
Recently, it has been demonstrated that Nrf2 modulation can protect neurons from
parkinsonian agents and, in some instances, reverse motor symptoms of animal models.
Furthermore,  baseline  aberrations  of  Nrf2  and  its  associated  pathway  have  been
reported in PD patients, and genetic variability—within and around the Nrf2 gene—
may  modify  PD  susceptibility  and  onset.  Overall,  Nrf2  dysregulation  has  been
tentatively implicated in the pathogenesis of PD and may prove to be an effective
therapeutic target.
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1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a range of motor
and nonmotor features. Clinically, PD diagnosis is based on the presence of distinctive cardinal
motor features, including bradykinesia, resting tremor, postural instability, and rigidity [1].
Disease progression can be staged in accordance with developing neuropathological hall‐
marks that advance through presymptomatic and symptomatic phases [2]. The presympto‐
matic stages may last years to decades before the manifestation of classical PD‐related motor
symptoms [3–5].  Motor dysfunction is  commonly associated with the loss  of  dopamine‐
producing neurons in the substantia nigra pars compacta, projecting throughout the nigrostriatal
pathway. Further progressive and selective neuron loss will continue, ultimately culminating
in a debilitating multisystem disorder [6].
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Currently, the most efficacious medical treatments are limited to dopamine replacement
therapies (levodopa), however, such medications wane in efficacy and can produce debilitating
motor and nonmotor symptoms, prompting alternative approaches [7, 8]. Generally, PD
medications agonize dopaminergic receptors, antagonize cholinergic receptors, and/or
prolong dopamine activity (monoamine oxidase type‐B inhibitors) [8]. While these approaches
address symptoms, they provide no curative or disease‐modifying effect, provoking research‐
ers to isolate the pathogenic mechanism/s that underpin dopaminergic degeneration.
While the majority of PD cases are idiopathic (90–95%), etiological risk has been attributed to
herbicide/pesticide exposure, heavy metals, rural living, aging, and genetic variability [9–11].
The role of these contributing factors in the pathogenesis of PD can be summarized as a
complex interaction of environmental and genetic influences on a background of aging.
Regardless of etiology, significant clinical advances rely on identifying the common biological
pathways that underpin neuronal degeneration. Increasing evidence in this field suggests that
oxidative stress is a major contributor in this process.
Free radicals, including reactive oxygen species (ROS) and reactive nitrogen species, are
endogenous molecules, produced in cells as a by‐product of metabolic systems (such as
mitochondrial oxidative phosphorylation) and/or in response to an altered chemical environ‐
ment. ROS are molecular species that contain an unpaired electron and are unstable and
reactive. They are often implicated in disease (including numerous neurodegenerative
diseases) and consist of hydroxyl, hydrogen peroxide, oxygen singlet, and superoxide radicals.
Within a “steady‐state” environment, the levels of ROS are often balanced by endogenous
antioxidant defense mechanisms. However, if this balance is disrupted in the favor of ROS
accumulation, a condition referred to as oxidative stress arises. Mitochondrial dysfunction,
inflammation, and exercise are common endogenous generators of ROS. Environmental
generators of ROS include cigarette smoke, pesticide exposure, and radiation. Overexposure
to one or more of these factors may result in oxidative stress. Additionally, oxidative stress
may occur if normal production of these reactive species cannot be appropriately managed.
Thus, an inefficient antioxidant response mechanism may also result in increased risk for
oxidative stress. An inability to balance redox systems and dispose of damaged cellular
components may exacerbate ROS production and dramatically affect the survival of the cell
through ROS‐mediated lipid, protein, and DNA oxidation [12].
In general, neuronal cells are vulnerable to oxidative changes because of their high oxygen
consumption and enrichment in fatty acids [13]. Furthermore, dopaminergic neurons are
especially prone to oxidative‐induced injury due to their capacity to produce ROS as a
metabolic by‐product. This can occur in two ways: (1) when dopamine is metabolized
enzymatically (via monoamine oxidase) or (2) through auto‐oxidation of dopamine (ultimately
forming neuromelanin) [14]. Both means of processing dopamine produce ROS; enzymatic
oxidation (1) forms hydrogen peroxide (H2O2), and nonenzymatic oxidation (2) produces
superoxide (O2−) and reactive quinones [15]. The production of ROS may be exacerbated by
inflammation, neuronal damage, impaired mitochondrial management, and dysfunctional
antioxidant response mechanisms [16]. However, the vast majority of ROS has been attributed
to the mitochondria.
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The major source of cellular energy (ATP) is produced by the mitochondria. This system is
dependent on the simultaneous generation of a proton‐motive force (termed the electron
transport chain; ETC) across the mitochondrial inner membrane, driving the formation of ATP.
The mitochondrial ETC came to the forefront of PD research after studies reported that 1‐
methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP), a mitochondrial ETC complex I inhibitor,
induced Parkinsonian symptoms as a result of a toxic insult on nigrostriatal neurons [17].
Following these initial studies, complex I deficits have been identified not only in pharmaco‐
logically induced cases but also in idiopathic PD cases [18].
Endogenous antioxidants are required to maintain redox balance throughout the system.
Many are transcriptionally regulated by the antioxidant “master regulator” Nrf2, which, upon
direct stimulation from electrophilic compounds and ROS, will translocate to the nucleus and
activate gene transcription of a gamut of antioxidant enzymes. Nrf2 supports and regulates,
among others, the most abundant antioxidant family in the cell, glutathione. Interestingly,
deficiency of reduced glutathione (GSH)—in the substantia nigra of PD brains—has consistently
been reported [19, 20]. Recently, the Nrf2‐mediated antioxidant response pathway has been
directly and indirectly implicated in PD. This chapter will explore the role of Nrf2 and its
pathway, in the development and management of PD, as stated within the contemporary
literature.
2. The role of oxidative stress in Parkinson’s disease
For years, markers of oxidative stress have been observed in postmortem brain tissue and
disease models of PD. Currently it is unclear whether these factors are primary causes of PD
or the result of established neurodegeneration. Regardless, studies have demonstrated that
chronic ROS exposure can lead to the exacerbation of dopaminergic neuron death; implicating
these processes in the pathophysiology of PD.
2.1. Mitochondria and oxidative stress
The brain is a major producer of ROS due to its extensive oxygen consumption; the nervous
tissue is responsible for ~20% of total body oxygen consumption. The tightly regulated
signaling systems of these neurons have a high energy demand provided primarily by the
oxygen‐dependent ATP production of the mitochondria. The ability of the mitochondria to
fuse, divide, and migrate throughout the extended processes of neurons provide a dynamic
adaptability in order to meet metabolic demands [21, 22]. Under normal resting conditions,
mitochondria produce the ROS precursor molecule, superoxide (O2•−), as a by‐product of the
electron transport chain. O2•− can produce hydrogen peroxide (H2O2) and hydroxyl (•OH);
endogenous free radicals that can initiate lipid peroxidation. The brain is especially sensitive
to lipid peroxidation due to the high concentration of polyunsaturated fatty acids. Because of
this, neurons cells are extremely sensitive to the oxidative environment caused by mitochon‐
drial defects; a number of these mitochondrial deficiencies have been implicated in neurode‐
generative diseases, such as PD.
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In the late 1970s, drug addicts presenting with Parkinsonian‐like symptoms led to the discov‐
ery of MPTP, a contaminant of illicit meperidine synthesis (a synthetic analogue of heroin).
Soon after its discovery, MPTP was used to produce a clinical phenotype, indistinguishable
from PD, in primate species [23]. MPTP was shown to oxidize intraneuronally, the effect of
which (underscored amongst other clinical hallmarks) was the selective destruction of
dopaminergic neurons in the nigrostriatal system. More recently, a number of pesticides/
herbicides have also demonstrated their efficacy as neurotoxins. Rotenone, a common
herbicide, is often used in a manner similar to MPTP, to induce dopaminergic neurodegener‐
ation in animal models. Both MPTP and rotenone, mechanistically, act upon the same pathway
and inhibit complex I of the mitochondrial oxidative phosphorylation pathway [17]. Following
these initial studies, complex I deficits have been identified not only in pharmacologically
induced cases but also in idiopathic PD cases [18]. Furthermore, this reduction of complex I
activity is not localized to the substantia nigra, but has been found in skeletal muscle, platelets,
and fibroblasts of PD patients [24–27]. This evidence further implicates mitochondrial main‐
tenance and subsequent free radical production in the pathogenesis of PD.
While the majority of PD is sporadic, rare genetic forms of the disease have been identified. So
far, 23 chromosomal loci, termed the PARK loci, have been linked to both autosomal‐dominant
and autosomal‐recessive inheritance patterns of PD. Interestingly, mutations within many of
these loci have been associated with mitochondrial dysfunction and oxidative stress.
Dominantly inherited mutations in the alpha‐synuclein (SNCA) gene were the first identified
genetic forms of familial PD. Alpha‐synuclein is the major proteinaceous constituent of the
Lewy body, the key pathological hallmark of PD and other so‐called synucleinopathies. This
protein provided the first solid link between sporadic and familial forms of Parkinson’s disease.
Currently, studies suggest that, normally, alpha‐synuclein plays a “protective role” as a
chaperone, sequestering dysfunction proteins into aggregates [28–30]. However, these
aggregates may lead to synaptic degeneration and ultimately cell death [31]. More recently,
studies have suggested that alpha‐synuclein aggregation can be induced by increased levels
of ROS as a consequence of mitochondrial dysfunction, in vitro [32, 33]. Moreover, alpha‐
synuclein aggregation may further damage mitochondria, compounding the effects of
oxidative stress [34].
Mutations within three PARK loci—PARK2 (gene: PARK2; protein: Parkin), PARK6 (gene:
PINK1; protein: PINK1), and PARK7 (gene: PARK7; protein: DJ‐1)—are inherited in an auto‐
somal recessive manner and have been linked to early‐onset PD (i.e., symptoms present
<45 years of age). Interestingly, animal genetic models have identified common and converging
pathways for these gene products; these pathways focus on mitochondrial maintenance/
dynamics, oxidative stress, and disrupted antioxidant pathways [35]. Individual disease
models that knockout these genes result in increased susceptibility to H2O2 and excess ROS
production [36–40]. Overall, converging evidence implicates certain PARK gene products in
mitochondrial maintenance and ROS management. Subsequent dysfunction of these pathways
therefore suggests that oxidative stress plays a central role in PD pathogenesis.
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2.2. Dopamine metabolism and oxidative stress
As previously discussed, mitochondrial defects are associated with increased free radical
production, and this has been theorized to play an important role in the pathogenesis of PD.
However, these effects may be compounded by the ROS‐enriched environment of highly
metabolic dopamine‐producing neurons. Dopamine can be metabolized enzymatically (via
monoamine oxidase) or through auto‐oxidation (ultimately forming neuromelanin) [14]. Both
means of dopamine‐processing produce ROS; enzymatic oxidation forms H2O2, and nonen‐
zymatic oxidation produces O2− and reactive quinones [15]. Production of ROS may be
exacerbated by inflammation, neuronal damage, impaired mitochondrial management, and
dysfunctional antioxidant response mechanisms [16].
Current evidence supports the hypothesis that PD is a consequence of genetic variation and
environmental exposures, converging—ultimately—on oxidative stress. Therefore, it is
important to characterize the role of antioxidant‐response mechanisms, specifically Nrf2—
commonly touted as the “master regulator” of oxidative stress—in the pathophysiology of PD.
3. Nrf2 in Parkinson’s disease progression and pathology
Maintaining redox balance within an aging brain is reliant upon an efficient and an effective
Nrf2‐mediated pathway. However, aging appears to correlate with a decline in Nrf2 expression
and transcriptional response, potentiating an individual’s susceptibility to ROS accumulation
[41, 42].
Nrf2 protein concentration, when isolated from the cerebral spinal fluid of PD patients with
LRRK2 mutations (G2019S), was positively, and significantly, associated with disease duration,
motor scores, and the Unified Parkinson’s Disease Rating Scale (UPDRS; well‐established
rating scale of Parkinson’s disease symptom severity) [43]. This indicates that Nrf2 concentra‐
tion (at least in the CSF) may increase with disease progression. Moreover, Nrf2 location may
change in response to the oxidative profile of the cellular environment. This is also highlighted
in a study that demonstrated that Nrf2 was found in the nucleus of nigral dopaminergic
neurons in early Braak staging (1–2) PD patients, while a cytosolic localization was predomi‐
nantly found for healthy, age‐matched controls [44]. This translocation of Nrf2 to the nucleus
in PD patients indicates an attempt to upregulate antioxidant responsive genes. Of these, the
potent and diverse antioxidants, NQO1 and HO‐1, are two that are strongly enhanced by Nrf2
activation. NQO1 is a successful metabolizer of dopamine‐derived quinones [45] and has been
reported at higher levels within the subtantia nigra pars compacta of PD patients compared to
healthy controls [46]. NQO1 overexpression appears to protect cells against dopamine‐
mediated mitochondrial damage in vitro [47] and in vivo reduces MPTP toxicity [48]. Another
Nrf2‐transcribed antioxidant, HO‐1, is also observed at higher concentrations in PD patients’
blood serum compared to healthy controls [49]; the higher HO‐1 concentrations were not
observed in the blood serum of Alzheimer’s disease patients, suggesting a disease‐dependent
Nrf2 recruitment. Unlike NQO1, no disease‐specific differences for HO‐1 expression have been
observed in the substantia nigra pars compacta of PD patients. However, PD patients exhibiting
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Lewy body pathology had a distinct HO‐1 staining pattern within the periphery of these
proteinaceous Lewy body inclusions [50]. This curious finding demonstrates the oxidative
nature of Lewy bodies and the relationship between the Nrf2 pathway and PD pathology.
It is well established that the Nrf2 pathway is an integral player in the cellular response to the
oxidative stress commonly associated with PD. It follows that a dysfunctional Nrf2 response
may interfere with the normal healthy antioxidant management, and there is evidence that
this contributes to risk for disease [51]. A number of studies have reported reduced antioxidant
enzyme activity in the substantia nigra pars compacta of PD patient brains [52, 53]. Also,
contemporary evidence suggests that genetic variability, in and around the Nrf2 encoding
gene, is associated with disease susceptibility and modulates disease age‐at‐onset [11, 54, 55].
4. Nrf2 genetics and Parkinson’s disease
Oxidative stress appears to lie at the nexus of genetic, pharmacologically induced, and
idiopathic cases of Parkinsonism. Considering this, studies have begun to investigate the
degree of influence that transcriptional “master regulators” of antioxidant response may
impose on disease pathogenesis. A recent study has comprehensively screened NFE2L2, the
gene that encodes Nrf2, for genetic sequence variants and correlated genetic variability with
disease susceptibility [11]. Prior to this report, few candidate gene studies had investigated
this relationship. A Taiwanese case–control study (PD = 480; controls = 526), which genotyped
three Nrf2 promoter single nucleotide polymorphisms (SNPs), did not observe any significant
individual polymorphism associations with PD [56]. Interestingly, a Polish case–control group
reported that a specific haplotype (comprising these three promoter SNPs) was associated with
disease protection and a delayed age‐at‐onset of PD. A further publication suggested that
haplotypes of eight other SNPs found within and around NFE2L2 altered disease risk and
disease age‐at‐onset within two independent case–control groups (Polish and Swedish) [55].
This study was subsequently replicated in a European meta‐analysis and in a larger Australian
case–control study. The European case–control study (PD = 1038; controls = 1600) re‐established
the previously identified protective and disease‐delaying Nrf2 promoter SNP haplotype and
a number of individual polymorphisms associated with both earlier and delayed PD age‐at‐
onset [54]. A large Australian study (PD = 1338; controls = 1379) further replicated the disease‐
delaying Nrf2 promoter haplotype and identified a SNP associated with an reduced disease
risk [11]. Recently, two novel Nrf2‐coding SNPs were identified and associated with PD within
a Chinese population [57]. This study further demonstrated that overexpressing these alternate
alleles reduced the expression of downstream Nrf2 products—glutathione s‐transferase and
HO‐1. These studies provide compelling evidence that genetic variability within and around
Nrf2 modulates PD risk and susceptibility. Due to the important role of Nrf2 as a functional
respondent to oxidative threat, it is important to understand its influence on PD in the context
of environmental exposures.
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5. Nrf2 and environmental exposures in Parkinson’s disease
A number of exogenous agents have shown to influence the development of PD; heavy metals
(iron, copper, cadmium, manganese), insecticides/herbicides, and organic solvents are often
reported in human epidemiological and animal studies [9, 10, 58]. Nrf2 stabilization from its
constitutive repressor, KEAP1, and subsequent translocation to the nucleus are dependent
upon exposure to electrophilic compounds and oxidative stress [59]. Some of the previously
mentioned exogenous agents, implicated in PD, upregulate the Nrf2 signaling pathway as a
response to mitigate potential damage [60]. The heavy metals, copper and iron, have been
linked to oxidative stress and alpha‐synuclein aggregation in PD. Experimental data have
shown that accumulated ferrous iron downregulates Nrf2 and HO‐1 expression, in vitro,
promoting alpha‐synuclein aggregation [61]. Furthermore, overexpression of HO‐1 mitigates
ferrous iron‐induced cellular damage. Also, the ROS‐mediated neurotoxic effects of excess
copper exposure have shown to induce the Nrf2 pathway in zebrafish [62]. Acute cadmium
exposure, tentatively associated with Parkinsonism [63], and manganese, known to produce
Parkinson’s‐like motor dysfunction [64], both induce Nrf2 transcriptional activity in vivo [65].
Pesticide/herbicide exposures, classified as risk factors for PD, induce oxidative stress as a
mechanism of neuronal cell death [66, 67]. The pesticide, deltamethrin, activates Nrf2 and
downstream gene expression in rat brains [68]. Furthermore, Nrf2 activation protects neuronal
cell lines from paraquat—a herbicide used to produce Parkinsonism in animal models. This
data tentatively support the hypothesis that the Nrf2 pathway is modulated in response to PD‐
associated environmental exposures. Further studies have investigated whether genetic
variability underlying Nrf2 and its various downstream products affect their cytoprotective
activity in response to environmental insult.
One study observed that human olfactory neurosphere‐derived cell lines carrying the minor
allele of an Nrf2 SNP were significantly resilient to rotenone‐induced cell death over a 5‐day
exposure [11]. In addition to Nrf2, PD risk from pesticide exposure has been associated, within
certain populations, with genetic variability of Nrf2‐transcribed genes. Individuals carrying
NQO1 SNPs are more susceptible to PD when exposed to pesticide compared to exposed
individuals not carrying the variant [69]; while GST genotype has also shown to influence PD
susceptibility upon exposure to paraquat [70, 71].
6. Nrf2 modulation as a neuroprotective strategy
As demonstrated in the literature, oxidative stress is highlighted as a major contributing factor
in the pathogenesis of PD. Genetic, environmental, and idiopathic cases of PD have reported
ROS imbalance, thereby tentatively implicating the “master regulator” of oxidative manage‐
ment, Nrf2, in the pathophysiological process. Numerous studies have decided to evaluate
whether modulating Nrf2—either genetically or pharmacologically—influences disease
susceptibility in vitro or in vivo. Table 1 summarizes a number of these studies.
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Target  Intervention Model  Neuroprotective against:  References
Nrf2 Dimethyl fumarate
(DMF)
Alpha‐synuclein mouse
model
Dopamine neuron loss in substantia
nigra
 [78]
Overexpression Mouse H2O2 −and glutamate‐treated cortical
neurons
 [79]
Overexpression Mixed primary neuron
culture
Rotenone/ionomycin‐induced cell
death
 [84]
DMF1,2 Mouse1 SH‐SY5Y cells2 MPTP‐induced neurotoxicity1, 6‐
OHDA‐treated cells2
 [85]1, [86]2
NQO1 Overexpression SK‐N‐MC
neuroblastoma 
Dopamine‐induced toxicity  [47]
Nrf3,4,
NQO19
Triterpenoids3
KMS040144,9
C57B16 mouse3,4,9 MPTP‐induced dopaminergic neuron
toxicity3,4,9
 [48]4, [87]3, [88]9
Nrf25,6,10,
NQO15,6,
HO‐15,6
Bromocriptine5,
torularhodin6,
Selegiline7
PC12 cells5,6,7 H2O2‐induced oxidative damage5,6,
MPP+‐induced oxidative damage7
 [89]5, [90]6, [83]7
Nrf2,
NQO1,
HO‐1
α‐Iso‐cubebene HT22 cells Glutamate‐induced oxidative damage  [91]
NQO18,9,
HO‐19
KMS040148,
isothiocyanate‐39
CATH.a cells8,9, BV‐2 cells9 H2O2/MPP+−treated cells8,
lipopolysaccharide‐treated cells9
 [48]8, [88]9
Superscript 1–9 denotes information obtained from a single source.
Table 1. Nrf2 and neuroprotection.
The ability of Nrf2 to attenuate disease relevant perturbations has been evaluated in neuronal
cell line derivatives and various animal models. Many of these studies utilize a post‐treatment
strategy, perturbing the cells after Nrf2 is upregulated. Nrf2 activation can be influenced either
pharmacologically (e.g., dimethyl fumarate (DMF), sulforaphane (SFN), or with tert‐butyl
hydroquinone (tBHQ)) or genetically. Perturbations are often performed with known Parkin‐
sonian agents such as paraquat, rotenone, MPTP, 6‐hydroxy dopamine (6‐OHDA), or hydro‐
gen peroxide (H2O2). This approach has consistently demonstrated that Nrf2 activation
provides a successful neuroprotective strategy [72–77]. However, it must be noted that
modulating Nrf2, prior to toxic treatment, does not reflect the insidious nature of PD and does
not take into consideration the decades of accumulated cellular damage that has existed prior
to clinical intervention. Notwithstanding this caveat, animal models of PD are providing
compelling evidence that Nrf2 modulation offers significant protection against neuronal cell
loss.
Current PD mouse models can recapitulate the histological hallmark of alpha‐synuclein‐
containing aggregates and selective nigral dopaminergic neuron loss. The pharmacological
targeting of Nrf2 in these models, via oral administration of DMF, can attenuate dopaminergic
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neuron loss in the substantia nigra [78]. Interestingly, this effect was not observed in Nrf2
knockout mice. Furthermore, Nrf2 knockout mice are more susceptible to cortical neuron cell
damage caused by H2O2 and glutamate, while, on the other hand, they are significantly
protected when Nrf2 is overexpressed [79]. Some studies have also shown that, in addition to
Nrf2 overexpression, Keap1 repression may offer a successful strategy to restore neuron
degeneration and motor dysfunction in an alpha‐synuclein Drosophila model of PD [80].
To date, no studies have directly evaluated the efficacy of pharmacologically targeting Nrf2 as
a treatment strategy for PD. Since the 1990s, the drug deprenyl (selegiline)—a type‐B monoa‐
mine oxidase inhibitor (MAOI‐B)—has been used as a pharmacological means to treat PD. The
mechanism of action of MAOI‐B is to inhibit the breakdown of monoamine neurotransmitters
(such as dopamine). While this strategy temporally maintains synaptic dopamine concentra‐
tions, it also reduces the oxidative stress associated with dopamine metabolism [81]. While it
has been known, since early in its use, that selegiline induced the expression of antioxidant
enzymes [82], it has only recently been discovered that this is mediated by the activation of
Nrf2 [83] and that activation of this pathway was sufficient to protect a neuronal‐based cell
line from oxidative damage.
7. Conclusion
Oxidative stress has been identifided as a major contributor in the pathogenesis of PD.
Mechanisms of ROS production—contributing to the oxidative profile of neuronal cells—
include mitochondrial respiration, dopamine metabolism, and environmental exposures.
Normally, redox balance is managed by the transcription factor and antioxidant “master
regulator,” Nrf2. Studies have demonstrated that Nrf2 and its associated pathway products
can be upregulated in PD patient brains; potentially, this highlights the body’s attempt to
mitigate oxidative stress. Furthermore, studies have also shown that reduced or dysfunctional
Nrf2 can be found in PD tissue. Genetic variability within and around the Nrf2 gene has been
associated with PD risk and age‐at‐onset, while genetic aberrations in Nrf2‐mediated genes
may influence an individual’s risk of PD after exposure from environmental agents. Due to the
functional role of Nrf2 in mitigating oxidative stress, many studies have investigated Nrf2 as
a modulator of Parkinson’s disease. Activation of Nrf2 attenuates neuronal damage caused by
Parkinsonian agents, in vitro and in vivo. Overall, Nrf2 has been tentatively implicated in the
pathophysiology of PD and may prove to be an effective therapeutic target.
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